TCR2 is a pharmaceutical company utilizing its proprietary TRuC platform to engineer T cells that target and eliminate solid tumor cancers. This approach aims to enhance the efficacy of cancer treatment by harnessing the patient's own immune cells for a more personalized therapeutic response.
Funding
$25M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Solid tumor cancers remain difficult to treat effectively due to their complex microenvironments and resistance to traditional therapies. Current treatment options often lack the specificity needed to target cancer cells while sparing healthy tissue, leading to significant side effects and limited efficacy.
Solution
TCR2 Therapeutics is developing a novel approach to cancer treatment using its proprietary TRuC-T cell platform. This technology engineers a patient's own T cells to specifically recognize and eliminate solid tumor cells. By harnessing the power of the immune system, TRuC-T cells offer a personalized and targeted therapy designed to overcome the limitations of conventional cancer treatments. The engineered T cells are designed to precisely target and destroy tumor cells, potentially leading to improved patient outcomes and reduced toxicity. This approach aims to provide a more effective and durable response against solid tumors.
Target Audience
The primary target audience includes patients with solid tumor cancers who have limited treatment options, as well as oncologists and hematologists seeking innovative therapies.
Features
- TRuC (T cell Receptor-like antibody Construct) platform for engineering T cells
- Engineered T cells designed to specifically target solid tumor antigens
- Personalized cell therapy approach using a patient's own immune cells
- Potential for enhanced efficacy and reduced toxicity compared to traditional therapies